Early anticoagulation may not up survival in severe COVID-19

Early anticoagulation may not up survival in severe COVID-19

(HealthDay)—Early therapeutic anticoagulation does not appear to affect survival among critically ill adults with COVID-19, according to a study published online Jan. 26 in the Annals of Internal Medicine.

Hanny Al-Samkari, M.D., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues evaluated the incidence of venous thromboembolism (VTE) and major bleeding in 3,239 critically ill adults with COVID-19 (67 hospitals; , 61 years; 64.5 percent men) and examined the effect of early therapeutic anticoagulation (within the first two days of intensive care unit [ICU] admission) on survival.

The researchers found that 204 (6.3 percent) developed VTE and 90 patients (2.8 percent) developed a major bleeding event. Male sex and higher D-dimer level on ICU admission were independent predictors of VTE. The analysis included 2,809 patients in the target trial emulation, with 11.9 percent receiving early therapeutic anticoagulation. During a median follow-up of 27 days, patients who received early therapeutic anticoagulation had a similar risk for death as those who did not (hazard ratio, 1.12; 95 percent confidence interval, 0.92 to 1.35).

"Our findings do not support early empirical use of therapeutic anticoagulation in critically ill patients with COVID-19," the authors write. "These findings highlight the need for well-designed, adequately powered randomized clinical trials of therapeutic in critically ill patients with COVID-19."


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: Abstract/Full Text
Journal information: Annals of Internal Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: Early anticoagulation may not up survival in severe COVID-19 (2021, January 28) retrieved 24 October 2021 from https://medicalxpress.com/news/2021-01-early-anticoagulation-survival-severe-covid-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors